Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Karolinska Development

1,02

 

SEK

 

+0,79 %

Mindre end 1K følgere

KDEV

NASDAQ Stockholm

Investment

Financials

Overview
Ownership
Investor consensus
Sammenligne
+0,79%
+15,38%
-1,92%
+7,03%
+2%
-38,18%
-59,84%
-60,69%
-97,12%

Karolinska Development is an investment company focused on long-term equity investments in biotechnology and pharmaceutical companies. The company's goal is to develop promising medical innovations stemming from academic research at Karolinska Institutet and other universities in the Nordic region. The company's portfolio includes companies in sectors such as biotechnology and medical technology. Karolinska Development was founded in 2003 and is headquartered in Solna, Sweden.

Læs mere
Markedsværdi
275,48 mio. SEK
Aktieomsætning
159,65 t SEK
Omsætning
1,84 mio.
EBIT %
-497,83 %
P/E
-
Udbytteafkast, %
-
Finanskalender
29.8
2025

Delårsrapport Q2'25

14.11
2025

Delårsrapport Q3'25

Alle
Selskabsmeddelelser
ViserAlle indholdstyper
Selskabsmeddelelsefor 20 timer siden

Karolinska Development’s Annual General Meeting 2025

Karolinska Development
Pressemeddelelse13.5.2025, 10.45

Karolinska Development’s portfolio company OssDsign has treated 10,000 patients with OssDsign Catalyst in the US

Karolinska Development
Pressemeddelelse7.5.2025, 06.50

Karolinska Development’s portfolio company Umecrine Cognition presents data validating novel clinical scale in PBC at EASL 2025

Karolinska Development

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Pressemeddelelse6.5.2025, 15.31

Carnegie Access: Karolinska Development: High discount to NAV – Q1(25) review

Karolinska Development
Pressemeddelelse5.5.2025, 06.50

Karolinska Development’s portfolio company Umecrine Cognition receives grant from The Michael J. Fox Foundation

Karolinska Development
Pressemeddelelse30.4.2025, 10.40

Karolinska Development portfolio company OssDsign will change CEO during second half of 2025

Karolinska Development
Selskabsmeddelelse30.4.2025, 06.00

Interim Report - January-March 2025

Karolinska Development
Selskabsmeddelelse7.4.2025, 12.46

Notice of Annual General Meeting in Karolinska Development AB (publ)

Karolinska Development
Pressemeddelelse1.4.2025, 11.00

Karolinska Development’s portfolio company Umecrine Cognition appoints new CEO

Karolinska Development
Pressemeddelelse1.4.2025, 06.50

Karolinska Development’s portfolio company Umecrine Cognition presents promising preclinical Parkinson data at AD/PD 2025

Karolinska Development
Selskabsmeddelelse21.3.2025, 07.00

Karolinska Development Annual Report 2024 published

Karolinska Development
Pressemeddelelse18.3.2025, 14.00

Karolinska Development’s portfolio company Umecrine Cognition provides update on ongoing Phase 1b/2a clinical study

Karolinska Development
Pressemeddelelse14.3.2025, 05.16

Carnegie Access: Karolinska Development: Highlights from Carnegie’s Healthcare Conference

Karolinska Development
Pressemeddelelse13.3.2025, 08.30

Karolinska Development’s portfolio company AnaCardio has been granted additional EU patent for drug candidate AC01

Karolinska Development
Pressemeddelelse12.3.2025, 14.23

Karolinska Development's portfolio company PharmNovo receives positive FDA feedback prior to IND application for Phase 2a trial

Karolinska Development
Pressemeddelelse25.2.2025, 08.10

Karolinska Development’s portfolio company AnaCardio includes first patient in a phase 2a study of its drug candidate AC01

Karolinska Development
Pressemeddelelse21.2.2025, 12.51

Carnegie Access: Karolinska Development: Several major inflection points in 2025

Karolinska Development
Pressemeddelelse18.2.2025, 13.17

Karolinska Developments portfolio company Promimic publishes positive results on reduction of bacteria growth on HAnano Surface

Karolinska Development
Selskabsmeddelelse14.2.2025, 07.00

Year-end Report - January-December 2024

Karolinska Development
Pressemeddelelse30.1.2025, 07.50

Karolinska Development’s portfolio company Dilafor advances tafoxiparin following successful meetings with FDA and European regulatory authorities

Karolinska Development
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.